Article Versions Notes

Hirabae A, Kuribayashi T, Tomida S, Okawa S, Nakasuka T, Nishii K, Nishimura J, Makimoto G, Ninomiya K, Higo H, et al. Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment. Current Oncology. 2026; 33(6):315. https://doi.org/10.3390/curroncol33060315

Hirabae, Atsuko, Tadahiro Kuribayashi, Shuta Tomida, Sachi Okawa, Takamasa Nakasuka, Kazuya Nishii, Jun Nishimura, Go Makimoto, Kiichiro Ninomiya, Hisao Higo, and et al. 2026. "Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment" Current Oncology 33, no. 6: 315. https://doi.org/10.3390/curroncol33060315

Hirabae, A., Kuribayashi, T., Tomida, S., Okawa, S., Nakasuka, T., Nishii, K., Nishimura, J., Makimoto, G., Ninomiya, K., Higo, H., Rai, K., Ichihara, E., Hotta, K., Sugimoto, M., Togashi, Y., Maeda, Y., Kiura, K., & Ohashi, K. (2026). Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment. Current Oncology, 33(6), 315. https://doi.org/10.3390/curroncol33060315